

Contents

1. THE PATIENT'S BRAIN: SETTING THE STAGE FOR UNDERSTANDING PLACEBO EFFECTS

1. A brief evolutionary account of medical care	5
Summary points	5
1.1 Simple organisms can take care of themselves	6
1.1.1 Unicellular organisms use simple strategies to protect themselves	6
1.1.2 The withdrawal reflex is present in both invertebrates and vertebrates	7
1.2 From the scratch reflex to grooming	8
1.2.1 The scratch reflex is a simple purposive behaviour	8
1.2.2 Grooming involves a complex behavioural repertoire	11
1.3 Scratching somebody else: a big evolutionary jump to social behaviour	13
1.3.1 Primates spend plenty of time in social grooming	13
1.3.2 From social grooming to altruistic behaviour	14
1.4 Taking care of the sick	17
1.4.1 From early forms of altruism to the emergence of the shaman	17
1.4.2 More rational treatments emerge slowly from prehistoric to historic medicine	20
1.5 Points for further discussion	21
2. Emergence and development of scientific medicine	24
Summary points	24
2.1 Emerging knowledge and the problem of animal experimentation	25
2.1.1 Scientific medicine requires basic anatomical and physiological knowledge	25
2.1.2 Acquiring new medical and surgical skills	27
2.1.3 Effective treatments need not be understood but they do need validation	31
2.1.4 Animal research impacts negatively on most people and raises many ethical concerns	34
2.2 Biological, psychological, and social factors all contribute to illness and healing	37
2.2.1 Modern scientific medicine includes a psychosocial component	37
2.2.2 Medical concepts vary across cultures but the psychosocial component stays the same	40

2.3	Medical practice meets neuroscience	43
2.3.1	Scientific medicine needs to include the study of the patient's and doctor's brain	43
2.3.2	To become and to be a patient involve four steps and relative brain processes	43
2.4	Points for further discussion	45
3.	Feeling sick: a combination of bottom-up and top-down events	49
	Summary points	49
3.1	The patient feels sick through both bottom-up and top-down processes	50
3.1.1	What is a symptom?	50
3.1.2	Detection of a symptom is a combination of interoception and other factors	51
3.1.3	Different brain regions respond to interoceptive stimuli	53
3.1.4	The insula plays a crucial role in awareness	55
3.1.5	Interoceptive awareness undergoes a top-down modulation	57
3.2	Bottom-up and top-down processes contribute to the global experience of pain	58
3.2.1	Pain experience is built up from the periphery to the central nervous system	58
3.2.2	There is not a single pain centre but a distributed system	61
3.2.3	Pain experience changes across individuals and circumstances	64
3.2.4	A complex neural network is responsible for the top-down modulation of pain	66
3.3	Emotions influence the perception of symptoms	68
3.3.1	Feeling sick does not necessarily mean physical suffering	68
3.3.2	Positive and negative emotions are processed in the limbic system	69
3.3.3	Anxiety about pain activates brain circuits that increase the pain	70
3.3.4	Anger and depression influence pain perception	75
3.4	Points for further discussion	76
4.	Seeking relief: the activation of motivational and reward circuits	88
	Summary points	88
4.1	Suppressing discomfort and seeking pleasure	89
4.1.1	Motivation is aimed at regulating internal states and at getting a reward	89
4.1.2	Suppressing discomfort from hunger, thirst, and thermal variations	91
4.1.3	Seeking the pleasure of sex	92
4.1.4	Reward-seeking behaviours involve the mesolimbic dopaminergic system	94
4.2	Suppressing discomfort from sickness	97
4.2.1	Seeking relief from sickness is a motivated behaviour	97
4.2.2	Motivated behaviour varies according to cultural differences	98
4.2.3	The motivation/reward system is activated when seeking and expecting relief	99
4.3	Points for further discussion	102

5. Meeting the therapist: a look into trust, hope, empathy, and compassion mechanisms	106
Summary points	106
5.1 Trusting the therapist	107
5.1.1 Trust in doctors can be measured	107
5.1.2 The amygdala is a key region in trustworthiness decisions	109
5.1.3 Oxytocin enhances trust	114
5.1.4 Admiration for virtue and for skills involves two separate neural systems	117
5.2 Sensory inputs can make the difference	118
5.2.1 Subtle differences in verbal communication may lead to different outcomes	118
5.2.2 Visual stimuli are the basis for nonverbal communication	119
5.2.3 Being touched by a beloved one makes the pain more bearable	125
5.3 The patient wants the future to be better than the present	127
5.3.1 Hope and hopelessness may impact on health	127
5.3.2 Hopelessness/helplessness involve serotonergic and noradrenergic systems	130
5.4 A look into the doctor's brain	131
5.4.1 Face expressions of pain are likely to have evolved for eliciting medical attention from others	131
5.4.2 Empathy and compassion have different meanings and mechanisms	132
5.4.3 There are two different neural systems for empathy	133
5.4.4 Compassion for social and physical pain engages two separate neural systems	136
5.4.5 Doctors can regulate their emotional responses to others' suffering	137
5.5 The doctor-patient interaction may have both positive and negative effects	139
5.5.1 A positive interaction may lead to positive outcomes	139
5.5.2 A negative interaction may lead to negative outcomes	142
5.6 Pain can be made a positive experience	143
5.7 Points for further discussion	144
6. The brain of the demented patient	155
Summary points	155
6.1 Many patients cannot communicate their discomfort	155
6.1.1 Who cannot communicate?	155
6.1.2 Dementia is a major medical problem	156
6.2 How the demented patient feels sick	158
6.2.1 The lateral and medial pain systems are affected differently in Alzheimer's disease	158
6.2.2 Vascular dementia may be associated to hyperalgesia	165
6.2.3 Frontotemporal dementia leads to reduced pain responses	166
6.3 The demented patient cannot seek relief	167
6.3.1 Purposive behaviour is impaired in dementia	167
6.4 The demented patient meets the therapist	168
6.4.1 There is no real interaction between the demented patient and the doctor	168
6.5 Points for further discussion	169

2. PLACEBO EFFECTS: GENERAL CONCEPTS AND MECHANISMS

7. The traditional concept of placebo	175
Summary points	175
7.1 The origin of the placebo concept and methodology	175
7.1.1 Many bizarre ineffective therapies were developed over the past centuries	175
7.1.2 When doctors became aware of the ineffectiveness of many therapies	178
7.1.3 The traditional concept of placebo effect is a first source of confusion	179
7.2 The placebo in clinical trials and medical practice	181
7.2.1 Placebos are the tenet of the randomized double-blind placebo-controlled trial design	181
7.2.2 Placebos may be used with other experimental designs	182
7.2.3 Placebos are widely used in routine medical practice	186
7.2.4 Psychologists consider the placebo effect as an example of the power of mind	187
7.3 Points for further discussion	189
8. A modern view of placebo and placebo-related effects	193
Summary points	193
8.1 What they are not	194
8.1.1 Many phenomena are mistakenly taken for placebo effects	194
8.1.2 Spontaneous remission is frequently and erroneously defined as placebo effect	194
8.1.3 Regression to the mean is common in clinical trials	197
8.1.4 Signal detection ambiguity can sometimes explain symptom 'reduction'	197
8.1.5 Sometimes patients and doctors give biased reports of the clinical condition	199
8.1.6 Co-interventions can sometimes be the cause of improvement	199
8.1.7 Classical clinical trials are not good for understanding placebo effects	200
8.2 What they are	203
8.2.1 Is the placebo effect different from the placebo response?	203
8.2.2 The psychosocial context around the therapy is the crucial factor	204
8.2.3 Placebo and nocebo effects occur when inert treatments are given	209
8.2.4 Placebo- and nocebo-related effects do not involve the administration of inert treatments	210
8.2.5 Are subjective outcomes different from objective outcomes?	211
8.3 How they work	212
8.3.1 There is not a single placebo effect but many	212
8.3.2 Expectation of a future outcome is one of the principal mechanisms	213
8.3.3 The placebo effect is a learning phenomenon	216
8.3.4 Some personality traits may be associated with placebo responsiveness	221
8.3.5 Genetics may affect placebo responding	222
8.3.6 Other possible explanations have been proposed	224
8.3.7 Placebo effects are also present in animals	225
8.3.8 What is the difference between placebo responders and non-responders?	226

8.4	Why they occur	227
8.4.1	Expectation-mediated placebo effects may be related to other self-regulatory processes	227
8.4.2	Are placebo and placebo-related effects a product of evolution?	229
8.4.3	Open-label placebos: why are they effective?	231
8.4.4	Do placebo effects occur on pre-existing nocebo effects?	232
8.5	Points for further discussion	232
9.	Placing placebo effects within the context of the doctor–patient relationship as a defence mechanism	244
	Summary points	244
9.1	A variety of defence mechanisms are present in living organisms	245
9.1.1	Cells respond to invaders and to damage	245
9.1.2	Living organisms protect themselves from a variety of dangers	247
9.2	Defence mechanisms can also involve cultural and social aspects	248
9.2.1	Thermoregulation as an example of physiological and cultural mechanism	248
9.2.2	Social groups can be advantageous to health in a number of ways	249
9.3	The doctor–patient interaction is a social mechanism of defence	250
9.3.1	The system works regardless of effective therapies	250
9.3.2	Why does the system work this way?	252
9.3.3	The doctor himself belongs to the system	253
9.4	Points for further discussion	254

3. DISEASE-BASED CLASSIFICATION OF PLACEBO EFFECTS: MOST STUDIED CONDITIONS

10.	Pain	259
	Summary points	259
10.1	Placebo analgesia	259
10.1.1	Placebo analgesia is the most studied type of placebo effect	259
10.1.2	Many factors influence the magnitude of placebo analgesia	260
10.1.3	Expectations of improvement may lead to analgesia	265
10.1.4	Painkillers are much less effective when administered covertly	267
10.1.5	Placebo analgesia is today the best model for studying endogenous mechanisms of analgesia	269
10.1.6	Some types of placebo analgesia are mediated by endogenous opioids	270
10.1.7	Some types of placebo analgesia involve the endocannabinoid system	275
10.1.8	Placebo analgesia is related to a reward dopaminergic system	277
10.1.9	Imaging the brain during placebo-induced expectations of analgesia	277
10.1.10	No prefrontal control, no placebo response	281
10.2	Nocebo hyperalgesia	282
10.2.1	Expectations of worsening may lead to hyperalgesia	282
10.2.2	Learning nocebo effects through observation	285
10.2.3	Negative expectations spread across different individuals	285
10.2.4	Nocebo hyperalgesia is mediated by cholecystokinin	288
10.2.5	Imaging the brain when expecting hyperalgesia	290
10.2.6	Positive mood can reduce nocebo effects	292
10.3	Points for further discussion	293

11. Diseases of the nervous system	303
Summary points	303
11.1 Parkinson's disease	303
11.1.1 Parkinson patients who receive placebo show a high rate of improvement	303
11.1.2 Expectations modulate Parkinsonian symptoms	304
11.1.3 Dopamine depletion in the striatum is the cause of Parkinson's disease	307
11.1.4 Placebo administration induces dopamine release in the striatum	309
11.1.5 The subthalamic nucleus neurons of Parkinson patients show abnormal activity	311
11.1.6 Placebos restore the normal activity of subthalamic nucleus neurons	312
11.1.7 Expectations of benefit can be as powerful as half dose of L-dopa	315
11.2 Deep brain stimulation and emotional processing	315
11.2.1 Expectations enhance the excitability of some limbic regions	315
11.2.2 Expecting an emotion may change its intensity	317
11.3 Migraine and headache	320
11.3.1 Subcutaneous placebos are better than oral placebos	320
11.3.2 Substantial clinical improvements occur in placebo groups in clinical trials of anti-migraine agents	321
11.4 Fatigue	323
11.4.1 Fatigue is very sensitive to placebo treatments	323
11.5 Sleep	324
11.5.1 Placebos for insomnia may induce behavioural and physiological changes	324
11.5.2 Restless legs syndrome shows improvements in placebo groups	325
11.6 Neurological disorders with a few or no available data	325
11.7 Points for further discussion	326
12. Mental and behavioural disorders	333
Summary points	333
12.1 Depression	333
12.1.1 The rate of improvement in placebo groups is high and has increased over the past years	333
12.1.2 Placebos and antidepressants affect similar areas of the brain	336
12.1.3 Some genetic polymorphisms are involved in the antidepressant placebo response	339
12.2 Anxiety	340
12.2.1 Anti-anxiety drugs are much less effective when given covertly	340
12.2.2 Imaging anxiety reduction after placebo administration	340
12.3 Dementia	343
12.3.1 Intensive follow-up can improve cognition in demented patients	343
12.3.2 Loss of prefrontal executive control affects placebo responsiveness	344
12.4 Addiction	346
12.4.1 Expecting a drug of abuse makes it more pleasurable	346
12.4.2 There is no definitive role of placebo and placebo-like effects in alcohol abuse	348
12.4.3 Tobacco smoking and nicotine intake show large placebo effects	350
12.4.4 Placebos can mimic and replace caffeine	351
12.4.5 Placebo response rates from cessation trials may inform on strength of addictions	352

12.5	Psychotherapy	352
12.5.1	Does psychotherapy work through a benign human relationship?	352
12.5.2	It is difficult to disentangle placebo effects from psychotherapy	353
12.5.3	The neural mechanisms of some psychotherapies differ from those of the placebo effect	355
12.5.4	Methodological recommendations for randomized controlled trials of psychological interventions have been proposed	355
12.6	Premenstrual dysphoric disorder	356
12.6.1	Placebos may reduce symptomatology through endogenous opioids	356
12.7	Attention-deficit hyperactivity disorder	357
12.7.1	Reducing drug intake through conditioned placebo responses	357
12.8	Mental disorders with no available data	357
12.9	Points for further discussion	357
13.	Immune and endocrine systems	366
	Summary points	366
13.1	Immunity and hormone secretion are subject to psychosocial influences	366
13.2	The immune system	367
13.2.1	Immune responses can be conditioned	367
13.2.2	Can conditioning of immune placebo responses affect the course of autoimmune diseases and allergies?	371
13.2.3	Specific and discrete neural networks are responsible for immune placebo effects	373
13.2.4	Several neurotransmitters are implicated in conditioned immune placebo effects	375
13.2.5	Inducing nocebo allergic reactions and adverse events	376
13.3	The endocrine system	377
13.3.1	Insulin conditioning can induce both hypoglycaemic and hyperglycaemic placebo responses	377
13.3.2	Inducing placebo insulin secretion	379
13.3.3	Hypothalamic–pituitary–adrenal activity can be conditioned	380
13.3.4	Conditioning but not expectation induces growth hormone and cortisol placebo responses	381
13.4	Points for further discussion	384
4. DISEASE-BASED CLASSIFICATION OF PLACEBO EFFECTS: LESS STUDIED CONDITIONS		
14.	Cardiovascular and respiratory system	393
	Summary points	393
14.1	The cardiovascular system	393
14.1.1	There are a few and contrasting placebo studies in cardiovascular health	393
14.1.2	Some cardiac effects can be conditioned	395
14.1.3	Placebo-induced activation of endogenous opioids may affect heart activity	396
14.1.4	Side effects are common in placebo groups of cardiovascular clinical trials	399

14.2	The respiratory system	400
14.2.1	Placebos can mimic the depressant effects of narcotics on ventilation	400
14.2.2	Placebos reduce bronchial hyper-reactivity in asthma	402
14.2.3	Cough is powerfully reduced by placebo treatments	405
14.3	Points for further discussion	406
15.	Gastrointestinal and genitourinary disorders	411
	Summary points	411
15.1	Gastrointestinal disorders	411
15.1.1	Reduction in gastrointestinal symptoms is common in patients who receive placebo treatments	411
15.1.2	Increasing the frequency of placebo administration increases clinical improvement	413
15.1.3	The placebo responses in irritable bowel syndrome can be imaged in the brain	415
15.1.4	Salivary secretion can be conditioned	417
15.1.5	Gastrointestinal symptoms can be learned	417
15.1.6	Placebo- and nocebo-induced expectations may lead to clinical improvement and worsening respectively	418
15.2	Genitourinary disorders	420
15.2.1	Reductions of subjective lower urinary tract symptoms are larger than reductions of objective symptoms in placebo groups	420
15.2.2	Sexual function may improve after placebo and worsen after nocebo	421
15.3	Points for further discussion	423
16.	Special medical conditions and therapeutic interventions	427
	Summary points	427
16.1	Oncology	427
16.1.1	Placebos may induce symptom reduction but not cancer regression	427
16.1.2	Cancer chemotherapy induces conditioned nocebo responses	428
16.2	Surgery	431
16.2.1	Patients undergoing placebo surgery show a high rate of improvement	431
16.2.2	Improvement may occur in those who believe they have received transplantation	432
16.3	Physical therapies	434
16.3.1	It is difficult to devise placebo physical therapies	434
16.4	Complementary and alternative therapies	435
16.4.1	Do complementary and alternative therapies work through placebo effects?	435
16.4.2	Acupuncture is likely to work through both specific and placebo effects	436
16.4.3	Expectations in acupuncture clinical trials can make a big difference	437
16.5	Itch	438
16.5.1	Substantial placebo and nocebo effects are present in itch	438
16.6	Other conditions with no available data	438
16.7	Points for further discussion	440

5. CLINICAL, ETHICAL, AND METHODOLOGICAL CONSIDERATIONS

17. Clinical–ethical implications and applications	447
Summary points	447
17.1 Assessing the effectiveness of new therapies	447
17.1.1 The debate of using placebos in clinical trials is still open	447
17.1.2 Two examples of the ethics of placebo trials: surgery and schizophrenia	456
17.1.3 New designs can be envisaged that increase the sensitivity of the trial	458
17.1.4 The new insights into placebo mechanisms lead to an uncertainty principle	460
17.2 Harnessing placebo and placebo-related effects in the clinic	465
17.2.1 Drug-like effects can be obtained without drugs	465
17.2.2 When doctors should treat their patients with placebos	468
17.2.3 Patients with prefrontal impairment need larger doses of analgesics	469
17.2.4 There is a danger behind the corner: does the science of placebo boost pseudoscience?	470
17.3 Points for further discussion	472
18. How to run a placebo study: a closer look into complex experimental designs	478
Summary points	478
18.1 What are we looking for?	478
18.2 Many arms are better than two	480
18.2.1 The 12-arms experiment with placebo, naloxone, and proglumide	480
18.2.2 The 12-arms experiment with placebo, naloxone, morphine, and ketorolac	482
18.2.3 The 6-arms experiment on the somatotopic effects of placebo and naloxone	484
18.2.4 The 4-arms experiment with nocebo, diazepam, and proglumide	485
18.3 Investigating sequence effects and learning	487
18.3.1 The design of expectation versus conditioning effects	487
18.3.2 The conditioning procedure for intraoperative recording	490
18.3.3 The experiment on learning	491
18.4 Comparing expected versus unexpected therapies	493
18.4.1 How to compare an open with a hidden treatment	493
18.4.2 The open–hidden paradigm in Alzheimer patients	494
18.4.3 The experiment with deep brain stimulation	495
18.5 Points for further discussion	495

6. BEYOND THE HEALING CONTEXT

19. Physical and cognitive performance	499
Summary points	499
19.1 Physical performance	499
19.1.1 Placebos boost physical performance	499
19.1.2 Should opioid-mediated placebo responses be considered doping?	504
19.1.3 Nocebos can counteract good physical performance	504

19.2	Performance at high altitude	505
19.2.1	High altitude is a model for both performance and hypoxia	505
19.2.2	Placebos work at very high altitudes under severe hypoxic conditions	508
19.2.3	Nocebo effects explain the interaction between biological and psychosocial factors	511
19.3	Cognitive performance	512
19.3.1	Placebos boost performance within the cognitive domain	512
19.4	Points for further discussion	514
20.	Everyday life	519
	Summary points	519
20.1	Halo effects are similar to placebo effects	519
20.2	Expectations modulate hunger and satiety	520
20.3	Points for further discussion	521
	<i>Index</i>	523